Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neurocrine Biosciences reports strong Q4 performance and eyes growth

Neurocrine Biosciences delivered strong performance in Q4 2022, with robust INGREZZA sales and a positive outlook for 2023, supported by significant investments in SG&A and R&D.
The company's focus on expanding into long-term care, advancing pipeline assets, and collaborations for innovative treatments positions it well for growth and addressing unmet needs.
While facing challenges in managing increased spending and market dynamics, Neurocrine remains optimistic about opportunities in expanding treatment reach, market penetration, and advancing clinical programs.

Neurocrine Biosciences reports strong Q1 performance and eyes international expansion

Neurocrine Biosciences had a strong Q1 performance with record sales, upcoming milestones, and disciplined expense management.
The company faces challenges in certain therapeutic categories but is optimistic about addressing unmet needs and expanding internationally.
Opportunities lie in innovative science, market positioning, and portfolio expansion, positioning Neurocrine for future growth.
Addressing concerns around drug interactions, dosing strategies, and trial risks will be crucial for maintaining clinical success and patient safety.

Neurocrine Biosciences excels in Q2, eyes growth opportunities ahead

Neurocrine Biosciences shows strong financial performance and growth prospects.
Focus on INGREZZA's persistency and pipeline advancements drives optimism.
Challenges include market dynamics and clinical trial complexities.
Opportunities lie in new indications, long-term care expansion, and telemedicine.

Neurocrine Biosciences excels in Q3, eyes growth in LTC segment

Neurocrine Biosciences delivered a strong Q3 performance with robust sales, positive regulatory developments, and promising pipeline advancements.
The company's focus on expanding indications, exploring combination therapies, and addressing market opportunities positions it for future growth.
While facing challenges in market evaluation and competition, Neurocrine Biosciences has opportunities to leverage its strengths and drive innovation.
Investors can look forward to upcoming events like the Analyst Day and R&D Day for deeper insights into the company's strategic direction and growth potential.

Neurocrine Biosciences excels in 2023, eyes Crinecerfont launch success

Neurocrine Biosciences had a strong 2023 with notable achievements in sales growth and pipeline advancements. While facing challenges in market dynamics and pricing negotiations, the company is well-positioned to leverage opportunities in upcoming launches and strategic growth initiatives.

Neurocrine Biosciences excels in Q1 with strong sales and pipeline advancements

Neurocrine Biosciences delivered a strong performance in Q1 2024, driven by robust INGREZZA sales, promising Phase II results for NBI-845, and advancements in Crinecerfont development.
The company's strengths lie in its diverse pipeline, financial stability, and strategic focus on chronic therapy and tolerability, positioning it for future growth and innovation.
While facing challenges in dosing optimization and revenue management, Neurocrine has opportunities to leverage its pipeline, explore new treatments, and differentiate its offerings in the market.

Neurocrine Biosciences excels in Q3, poised for growth ahead

Neurocrine Biosciences showcased robust performance in Q3, with strong INGREZZA sales and pipeline success, positioning for future growth.
The company's strengths lie in its expanded sales team, leadership quality, and commitment to innovation and value creation for shareholders.
Challenges include potential payer reimbursement issues, FDA interactions for Phase III strategy, and competitive pressures in the market.
Opportunities abound with upcoming regulatory approvals, pipeline advancements, and targeted commercial strategies for new product launches.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 2020 financial expense guidance. "Our focus remains on helping as many patients with...

Neurocrine Biosciences Reports Third Quarter 2020 Financial Results

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to Neurocrine Biosciences, Inc. (NASDAQ:NBIX) changed recently.

Was The Smart Money Wrong About Neurocrine Biosciences, Inc. (NBIX)?

Vertex Pharmaceuticals

Our indicative theme of Out Of Favor Healthcare Stocks Poised For Gains is down by about -13% year-to-date, compared to the S&P 500 which is up by about 2% over the same period. This theme includes healthcare and pharmaceutical companies that have shown robust historical revenue growth.

Vertex, Neurocrine: Are These Out Of Favor Healthcare Stocks A Buy As Vaccine Nears?

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Neurocrine Biosciences (NBIX) Q3 Earnings Expected to Decline

Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.

Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?

Credit Acceptance

RenaissanceRe Hlds

Investors seeking strong growth companies to invest in should watch Credit Acceptance Corporation, RenaissanceRe and Neurocrine Biosciences. The post 3 Companies to Invest In for Mammoth Growth in 2021 appeared first on InvestorPlace.

3 Companies to Invest In for Mammoth Growth in 2021

Alkermes

ACADIA Pharma

Arrowhead Pharmaceuticals

BioMarin Pharmaceutical

Ionis Pharma

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma companies that have shown strong historical revenue growth, improving fundamentals, and yet have not rallied.

ACADIA, Neurocrine, Alkermes Are Out Of Favor. Is It Time To Buy?

Alexion Pharma

Amgen

Gilead Sciences

With earnings season about to kick off, investors are being forced into a different sort of earnings season.

4 Very Profitable Biotech Stocks Expected to Soar Into 2021

SAN DIEGO and BOSTON, Oct. 7, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Boston-based Me2/Orchestra, the world's only known classical music organization created for people with mental illness and the people that support them, today announced that they have teamed...

Neurocrine Biosciences and Me2/Orchestra, in Partnership with Mental Health Advocacy Groups, Honor Mental Illness Awareness Week by Launching Monumental Moments™, an Online Community Platform and Charitable Initiative to Support, Inspire and Connect Peopl

SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, November 9, 2020. Neurocrine will then host a conference call and webcast to discuss its...

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results

SAN DIEGO, Sept. 28, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyses evaluating the efficacy and safety of ONGENTYS® (opicapone) capsules, recently approved by the U.S. Food and Drug Administration (FDA) as the first and only...

Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting

Ongentys, an add-on treatment for patients with Parkinson's disease, is entering the market soon.

Neurocrine Biosciences Is The Developer Of A New Cure For Parkinson's Disease

Neurocrine Presents Data, And Other News: The Good, Bad And Ugly Of Biopharma

Neurocrine Looks Like A Long-Term Value After Share Price Decline

New Data Support The Idea That Neurocrine Biosciences Is Building A Credible Parkinson's Portfolio

The much-anticipated launch of Ongentys has arrived.

Neurocrine Biosciences Officially Begins Marketing Its New Parkinson's Disease Drug

SAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.

Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

Voyager Therapeutics

Three years after treatment with NBIb-1817, Parkinson's disease patients still are still showing improvements.

Parkinson's Disease Patients Get Long-Term Benefits From Experimental Gene Therapy

SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.

Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020

SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.

Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.

Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings

SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.

Neurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual Conference

Ingrezza Remains Surprisingly Strong For Neurocrine

The biotech blew past Wall Street estimates with soaring sales of Ingrezza.

How Neurocrine Biosciences Crushed It in Q2

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2020 Results - Earnings Call Transcript

News for Neurocrine Biosciences Stock (NBIX)